1. The antitumor effect of a thermosensitive polymeric hydrogel containing paclitaxel in a peritoneal carcinomatosis model

   • Jieun Yu
   • Hyuk-Joon Lee
   • Han-Kwang Yang

   PRECLINICAL STUDIES 29 July 2010 Pages: 1 - 7

   

2. Antitumor and antiangiogenic effects of GA-13315, a gibberellin derivative

   • Yanli Zhang
   • Hui Zhang
   • Chen Qing

   PRECLINICAL STUDIES 14 August 2010 Pages: 8 - 16

   

3. Synthesis and antitumor activity of novel aroylthiourea derivatives of podophyllotoxin

   • Yu Zhao
   • Chengniu Wang
   • Li Zhu

   PRECLINICAL STUDIES 10 August 2010 Pages: 17 - 24

   

4. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression

   • Chithra D. Palani
   • James F. Beck
   • Jürgen Sonnemann

   PRECLINICAL STUDIES 03 August 2010 Pages: 25 - 36

   

5. Nutlin-1 strengthened anti-proliferation and differentiation-inducing activity of ATRA in ATRA-treated p-glycoprotein deregulated human myelocytic leukemia cells

   • Lei Zhang
   • Yan Yan
   • Qiaojun He

   PRECLINICAL STUDIES 05 August 2010 Pages: 37 - 47

   

6. K252a induces anoikis-sensitization with suppression of cellular migration in Epstein-Barr Virus (EBV)—associated nasopharyngeal carcinoma cells

   • Yuen-Keng Ng
   • Elaine Yue Ling Wong
   • Vivian Wai Yan Lui

   PRECLINICAL STUDIES 07 August 2010 Pages: 48 - 58

   

7. 17α-Alkynyl 3α, 17β-androstanediol non-clinical and clinical pharmacology, pharmacokinetics and metabolism

   • Clarence Ahlem
   • Michael Kennedy
   • James Frincke

   PRECLINICAL STUDIES 03 September 2010 Pages: 59 - 78

   

8. Expression of Nur77 induced by an n-butylidenephthalide derivative promotes apoptosis and inhibits cell growth in oral squamous cell carcinoma

   • Po Yen Liu
   • Jim Jinn-Chyuan Sheu
   • Horng Jyh Harn

   PRECLINICAL STUDIES 01 September 2010 Pages: 79 - 89

   

9. Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab

   • Erin R. Gardner
   • Martha Kelly
   • William D. Figg

   PRECLINICAL STUDIES 07 September 2010 Pages: 90 - 97

   

10. Salarin C, a member of the salarin superfamily of marine compounds, is a potent inducer of apoptosis

    • Nathalie Ben-Califa
    • Ashgan Bishara
    • Drorit Neumann

    PRECLINICAL STUDIES 24 August 2010 Pages: 98 - 104

    

11. 3β-acetyl tormentic acid induces apoptosis of resistant leukemia cells independently of P-gp/ABCB1 activity or expression

    • Gleice da Graça Rocha
    • Marisol Simões
    • Cerli Rocha Gattass

    PRECLINICAL STUDIES 04 September 2010 Pages: 105 - 113

    

12. Cytotoxic activity of the titanium alkoxide (OPy)₂Ti(4AP)₂ against cancer colony forming cells

    • Elizabeth A. Williamson
    • Timothy J. Boyle
    • Robert Hromas

    PRECLINICAL STUDIES 07 September 2010 Pages: 114 - 120

    

13. Paclitaxel effects on the proteome of HL-60 promyelocytic leukemic cells: comparison to peloruside A

    • Anja Wilmes
    • Ariane Chan
    • John Holmes Miller

    PRECLINICAL STUDIES 23 September 2010 Pages: 121 - 129

    

14. The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity

    • Nataly Tarasenko
    • Gania Kessler-Icekson
    • Ada Rephaeli

    PRECLINICAL STUDIES 23 September 2010 Pages: 130 - 143

    

15. Combining functional imaging and interstitial pressure measurements to evaluate two anti-angiogenic treatments

    • Ingrid Leguerney
    • Nathalie Lassau
    • Alain Roche

    PRECLINICAL STUDIES 06 October 2010 Pages: 144 - 156

    

16. Functional properties of synthetic N-acyl-L-homoserine lactone analogs of quorum-sensing gram-negative bacteria on the growth of human oral squamous carcinoma cells

    • Hongbo Chai
    • Masaharu Hazawa
    • Ikuo Kashiwakura

    PRECLINICAL STUDIES 28 September 2010 Pages: 157 - 163

    

17. Synthesis and biological evaluation of 2-amino-1-thiazolyl imidazoles as orally active anticancer agents

    • Wen-Tai Li
    • Der-Ren Hwang
    • Chiung-Tong Chen

    PRECLINICAL STUDIES 02 October 2010 Pages: 164 - 175

    

18. A novel aminosteroid of the 5α-androstane-3α,17β-diol family induces cell cycle arrest and apoptosis in human promyelocytic leukemia HL-60 cells

    • Hajer Jegham
    • Jenny Roy
    • Donald Poirier

    PRECLINICAL STUDIES 02 October 2010 Pages: 176 - 185

    

19. Antiangiogenic properties of an unusual benzo[k,l]xanthene lignan derived from CAPE (Caffeic Acid Phenethyl Ester)

    • Giuseppina Basini
    • Laura Baioni
    • Corrado Tringali

    PRECLINICAL STUDIES 06 October 2010 Pages: 186 - 190

    

20. The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma

    • Alejandro G. Levy
    • Peter E. Zage
    • Patrick A. Zweidler-McKay

    PRECLINICAL STUDIES 05 October 2010 Pages: 191 - 199

    

21. Adding a combination of hydroxycitrate and lipoic acid (METABLOC™) to chemotherapy improves effectiveness against tumor development: experimental results and case report

    • Adeline Guais
    • GianFranco Baronzio
    • Mohammad Abolhassani

    PRECLINICAL STUDIES 08 October 2010 Pages: 200 - 211

    

22. Riccardin D, a novel macrocyclic bisbibenzyl, induces apoptosis of human leukemia cells by targeting DNA topoisomerase II

    • Xia Xue
    • Xian-Jun Qu
    • Hong-Xiang Lou

    PRECLINICAL STUDIES 06 October 2010 Pages: 212 - 222

    

23. Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs

    • Jia-Jia Huang
    • Zhi-Ming Li
    • Tong-Yu Lin

    PRECLINICAL STUDIES 20 October 2010 Pages: 223 - 235

    

24. A thermally responsive biopolymer conjugated to an acid-sensitive derivative of paclitaxel stabilizes microtubules, arrests cell cycle, and induces apoptosis

    • Shama Moktan
    • Claudia Ryppa
    • Drazen Raucher

    PRECLINICAL STUDIES 12 October 2010 Pages: 236 - 248

    

25. Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies

    • Bryan J. Schneider
    • Gregory P. Kalemkerian
    • Maha Hussain

    PHASE I STUDIES 05 August 2010 Pages: 249 - 257

    

26. Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors

    • Biren Saraiya
    • Rashmi Chugh
    • Elizabeth A. Poplin

    PHASE I STUDIES 10 August 2010 Pages: 258 - 265

    

27. A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumors

    • Andrea Wang-Gillam
    • Susanne M. Arnold
    • A. Craig Lockhart

    PHASE I STUDIES 10 August 2010 Pages: 266 - 272

    

28. Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers

    • Yazdi K. Pithavala
    • Warren Tong
    • Karen J. Klamerus

    PHASE I STUDIES Open access 26 August 2010 Pages: 273 - 281

    

29. A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor

    • Shih-Hung Yang
    • Chia-Chi Lin
    • Ruey-Long Hong

    PHASE I STUDIES 01 September 2010 Pages: 282 - 289

    

30. Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine

    • Laura W. Goff
    • Al B. Benson III
    • Mace L. Rothenberg

    PHASE I STUDIES 21 September 2010 Pages: 290 - 298

    

31. A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors

    • Eduardo Vilar
    • Viktor Grünwald
    • Josep Tabernero

    PHASE I STUDIES 07 September 2010 Pages: 299 - 305

    

32. Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer

    • Chul Kim
    • Jae-Lyun Lee
    • Yoon-Koo Kang

    PHASE I STUDIES 14 September 2010 Pages: 306 - 315

    

33. Phase I and pharmacokinetic study of 3′-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies

    • Lisa A. Hammond-Thelin
    • Melanie B. Thomas
    • Eric K. Rowinsky

    PHASE I STUDIES 14 September 2010 Pages: 316 - 326

    

34. A Comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors

    • Aung Naing
    • Razelle Kurzrock
    • Patricia M. LoRusso

    PHASE I STUDIES 15 September 2010 Pages: 327 - 334

    

35. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma

    • Ana M. Molina
    • Darren R. Feldman
    • Robert J. Motzer

    PHASE II STUDIES 14 August 2010 Pages: 335 - 340

    

36. A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma

    • Simon Pacey
    • Martin Gore
    • Tim Eisen

    PHASE II STUDIES 05 August 2010 Pages: 341 - 349

    

37. A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer

    • Sung Yong Oh
    • Hyuk-Chan Kwon
    • Jung Hun Kang

    PHASE II STUDIES 13 August 2010 Pages: 350 - 356

    

38. A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer

    • Sung Sook Lee
    • Hei-Cheul Jeung
    • Sun Young Rha

    PHASE II STUDIES 24 August 2010 Pages: 357 - 363

    

39. A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma

    • Dale R. Shepard
    • Matthew M. Cooney
    • Jorge A. Garcia

    PHASE II STUDIES 14 August 2010 Pages: 364 - 367

40. Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity

    • Seok Jin Kim
    • Kihyun Kim
    • Won Seog Kim

    PHASE II STUDIES 24 August 2010 Pages: 368 - 375

    

41. Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients

    • Romain Coriat
    • Olivier Mir
    • François Goldwasser

    PHASE II STUDIES 27 August 2010 Pages: 376 - 381

    

42. Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium

    • Hedy Lee Kindler
    • Kristen Wroblewski
    • Everett E. Vokes

    PHASE II STUDIES 28 August 2010 Pages: 382 - 386

    

43. An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma

    • George P. Kim
    • Michelle R. Mahoney
    • Charles Erlichman

    PHASE II STUDIES 14 September 2010 Pages: 387 - 394

    

44. Combined treatment with Bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patients

    • Nikolaos Tsavaris
    • Ioannis F. Voutsas
    • Constantin N. Baxevanis

    PHASE II STUDIES 07 September 2010 Pages: 395 - 402

45. Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapy

    • Amélie Lansiaux
    • Sophie Salingue
    • Nicolas Penel

    SHORT REPORTS 07 May 2010 Pages: 403 - 404

46. In vivo anti-lymphoma activity of an agonistic human recombinant anti-TRAIL-R2 minibody

    • Giorgio Zauli
    • Federica Corallini
    • Paola Secchiero

    SHORT REPORT 17 August 2010 Pages: 405 - 407

    

47. Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer

    • Jae-Heon Jeong
    • So-Youn Jung
    • Jungsil Ro

    SHORT REPORT 05 October 2010 Pages: 408 - 416

    

48. Anti-leukemic activity of Dasatinib in both p53^wild-type and p53^mutated B malignant cells

    • Raffaella Bosco
    • Marco Rabusin
    • Paola Secchiero

    SHORT REPORT 16 October 2010 Pages: 417 - 422

    

49. A short report on article by V. Pruliere-Escabasse et al., Vol. 27: 285–286, 2009

    • Terence M. Davidson

    Letters to the Editor Open access 04 May 2010 Pages: 423 - 424